HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Trimetazidine

HCID 21109
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
5011-34-7
Standard SMILES
COc1ccc(CN2CCNCC2)c(OC)c1OC
InChIKey
UHWVSEOVJBQKBE-UHFFFAOYSA-N
Molecular formula
C14H22N2O3
Average molar mass
266.34 g/mol
Monoisotopic mass
266.16304257

Overview

1-[(2,3,4-trimethoxyphenyl)methyl]piperazine is an aromatic amine.

Names & identifiers

Preferred name
Trimetazidine
IUPAC
1-[(2,3,4-trimethoxyphenyl)methyl]piperazine
English name
Trimetazidine
Molecular formula
C14H22N2O3
Molecular weight
266.34

Names & synonyms

TRIMETAZIDINE5011-34-71-[(2,3,4-trimethoxyphenyl)methyl]piperazineTrimetazidinaTrimetazidinumDilatanN9A0A0R9S8Piperazine, 1-((2,3,4-trimethoxyphenyl)methyl)-DTXSID2048531Piperazine, 1-[(2,3,4-trimethoxyphenyl)methyl]-1-((2,3,4-trimethoxyphenyl)methyl)piperazineVastarel MR
Show more names
TRIMETAZIDINE HCLVasorelVasartelAKOS B006602TIMTEC-BB SBB007020ART-CHEM-BB B006602ART-CHEM-BB B014361Trimetazidine USP/EP/BP
RefChem:191732DTXCID9027998C01EB15225-690-21-(2,3,4-Trimethoxybenzyl)piperazineMFCD008682631-(2,3,4-Trimethoxy-benzyl)-piperazinePreductal

Database identifiers

CAS
5011-34-7
PubChem CID
21109
DTXSID
DTXSID2048531
ChEMBL
CHEMBL203266
ChEBI
CHEBI:94789
UNII

Properties

Computed structural properties

XLogP
1
Topological polar surface area
43 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
5
Rotatable bonds
5
Heavy atoms
19
Formal charge
0
Complexity
259

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

Pharmaceuticals -> Listed in ZINC15

LogP1.04
Dissociation ConstantspKa1= 4.45 ± 0.02 and pKa2= 9.14 ± 0.02

Physicochemical properties

Boiling point
2 · bp2 200-205°
Density
1.092 · 1.092±0.06 g/cm3(Predicted)
vapor pressure
0.003 Pa · 0.003Pa at 25℃
storage temp.
Hygroscopic, Refrigerator, Under inert atmosphere
solubility
Chlorofrom (Slightly), Methanol (Slightly)
form
Solid
pka
9.07 · 9.07±0.10(Predicted)
color
Colourless to Pale Yellow Gel
Stability
Hygroscopic

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H226 (66.7%): Flammable liquid and vapor [Warning Flammable liquids]

P210, P233, P240, P241, P242, P243, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P303+P361+P353, P304+P340, P305+P351+P338, P305+P354+P338, P316, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P363, P370+P378, P403+P233, P403+P235, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory InformationREACH registered substance: Trimetazidine (EC: 225-690-2)
Hazard Classes and CategoriesFlam. Liq. 3 (66.7%)

Toxicology

Drug Induced Liver Injury · 4 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Trimetazidine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Safety data

Signal word
Danger
Symbol(GHS)
GHS02,GHS07,GHS05
hazard_code
Xi
hazard_class
IRRITANT
Hazard statements
H226-H314-H412-H302

Chemistry & industry

Pharmacology

ATC Code · 3 items

C01EB15

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingTrimetazidine is 15% protein bound in plasma. Trimetazidine can bind to human serum albumin.
Pharmacodynamics · 1 item

Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. Patients should be counselled regarding the risk of use with reduced renal or hepatic function, worsening of extrapyramidal symptoms or other movement disorders, and risk of falls.

Mechanism of Action · 1 item

During myocardial ischemia, anaerobic metabolism takes over, increasing levels of lactic acid. The decreased intracellular pH and increased concentration of protons activates sodium-hydrogen and sodium-calcium antiport systems, raising intracellular calcium concentrations, finally leading to decreased contractility. This injury to the myocardium raises concentrations of catecholamines, which activate hormone sensitive lipase, and increasing fatty acid concentrations in plasma. When the myocardium is repurfused, fatty acid oxidation becomes the dominant form of ATP production, maintaining an acidic pH, and further exacerbating the injury. The mechanism of action of trimetazidine is not fully understood. Trimetazidine may inhibit mitochondrial 3-ketoacyl coenzyme A thiolase, decreasing long chain fatty acid β-oxidation but not glycolysis in the myocardium. The decreased long chain fatty acid β-oxidation is compensated for by increased use of glucose, preventing a lowered myocardial pH, and further decreases in contractility. However, another study suggests that 3-ketoacyl coenzyme A thiolase may not be trimetazidine's target, and that this mechanism may be incorrect.

Biological Half-LifeIn young, healthy subjects, the half life of trimetazidine is 7.81 hours. In patients over 65, the half life increases to 11.7 hours.
Metabolism/Metabolites · 1 item

Trimetazidine can be oxidized at the piperazine ring to form trimetazidine ketopiperazine. Trimetazidine can also be N-formylated, N-acetylated, or N-methylated at the piperazine ring to form N-formyltrimetazidine, N-acetyltrimetazidine, and N-methyltrimetazidine respectively. Alternatively, trimetazidine can be demethylated at the 2, 3, or 4 position of the 2,3,4-trimethoxybenzyl moiety to form 2-desmethyltrimetazidine, 3-desmethyltrimetazidine, or 4-desmethyltrimetazidine. The desmethyltrimetazidine metabolites can undergo sulfate conjugation or glucuronidation prior to elimination.

Related reactions

14 records
New reaction record
HRID 22261 reaction equation
HRID 22261As reactant
HRID 37177 reaction equation
HRID 37177As reactant
HRID 37178 reaction equation
HRID 37178As reactant
HRID 298576 reaction equation
HRID 298576As reactant
HRID 307602 reaction equation
HRID 307602As reactant
HRID 568735 reaction equation
HRID 568735As reactant
HRID 694702 reaction equation
HRID 694702As reactant
HRID 945736 reaction equation
HRID 945736As reactant
PreviousPage 1 of 2

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
N9A0A0R9S8
EC Number
225-690-2
Nikkaji
J8.797A
LogP
1.143 at · 1.143 at 25℃ and pH6
CAS DataBase Reference
5011 · 5011-34-7(CAS DataBase Reference)
FDA UNII
9 A0A0R9S8 · N9A0A0R9S8
NCI Drug Dictionary
trimetazidine
ATC code
1 EB15 · C01EB15
Comptox DTXSID
2048531 · DTXSID2048531
Symbol(GHS)
2 · GHS02,GHS07,GHS05
Signal word
Danger
Hazard statements
226 · H226-H314-H412-H302
Precautionary statements
260 · P260-P264-P280-P301+P330+P331-P303+P361+P353-P363-P304+P340-P310-P321-P305+P351+P338-P405-P501-P264-P270-P301+P312-P330-P501-P273-P501
Hazard Codes
Xi
HazardClass
IRRITANT
REACH Registrations
Active
REACH Registrations
Active
Precautionary statements
P260-P264-P280-P301+P330+P331-P303+P361+P353-P363-P304+P340-P310-P321-P305+P351+P338-P405-P501-P264-P270-P301+P312-P330-P501-P273-P501
MeSH Pharmacological ClassificationDrugs used to cause dilation of the blood vessels.
Absorption, Distribution and Excretion · 4 items

In elderly patients, a 35 mg oral modified release tablet reaches a mean Cmax of 115 µg/L, with a Tmax of 2.0-5.0 hours, and a mean AUC0-12 of 1104 h\*µg/L. In young, healthy patients, the same dose reaches a mean Cmax of 91.2 µg/L, with a Tmax of 2.0-6.0 hours, and an AUC0-12h 720 h\*µg/L.

Trimetazidine is 79-84% eliminated in the urine, with 60% as the unchanged parent compound. In a study of 4 healthy subjects, individual metabolites made up 0.01-1.4% of the dose recovered in urine. In the urine, 2-desmethyltrimetazidine made up 0-1.4% of the recovered dose, 3- and 4-desmethyltrimetazidine made up 0.039-0.071% each, N-methyltrimetazidine made up 0.015-0.11%, trimetazidine ketopiperazine made up 0.011-0.4%, N-formyltrimetazidine made up 0.035-0.42%, N-acetyltrimetazidine made up 0.016-0.19%, desmethyl trimetazidine O-sulphate made up 0.01-0.65%, and an unknown metabolite made up0.026-0.67%.

The volume of distribution of trimetazidine is 4.8 L/kg.

Trimetazidine clearance is strongly correlated with creatinine clearance. In eldery patients with a creatinine clearance of 72 ± 8 mL/min, trimetazidine clearance was 15.69 L/h. In young, healthy patients with a creatinine clearance of 134 ± 18 mL/min, trimetazidine clearance was 25.2 L/h.

Applications

Uses1-(2,3,4-Trimethoxybenzyl)piperazine is used in combination with atorvastatin in the treatment of coronary heart disease and angina pectoris.

Upstream & downstream products

Upstream raw materials

Sodium carbonate1-Piperazinecarbaldehyde2,3,4-Trimethoxybenzyl chloride4-[(2,3,4-TriMethoxyphenyl)Methyl]-1-piperazinecarboxylic Acid Ethyl Ester1-Chloromethyl-2,3,4-trimethoxybenzene2,3,4-Trimethoxybenzaldehyde1-BOC-Piperazine

Downstream products

Lomerizine hydrochloride

Additional notes

DefinitionChEBI: 1-[(2,3,4-trimethoxyphenyl)methyl]piperazine is an aromatic amine.